Monte Rosa Therapeutics (GLUE)
(Delayed Data from NSDQ)
$6.08 USD
+0.12 (2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $6.08 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Balance Sheet
Fiscal Year End for Monte Rosa Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 232 | 264 | 346 | 42 | -99,999 |
Receivables | 1 | 8 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 3 | 4 | 3 | 2 | NA |
Total Current Assets | 236 | 276 | 349 | 44 | NA |
Net Property & Equipment | 34 | 27 | 12 | 5 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 5 | 5 | 5 | 1 | NA |
Total Assets | 304 | 342 | 366 | 49 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 11 | 8 | 7 | 7 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 15 | 15 | 10 | 3 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 18 | 0 | 0 | 20 | NA |
Total Current Liabilities | 47 | 26 | 17 | 29 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 35 | 2 | 2 | 1 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 68 | NA |
Total Liabilities | 125 | 71 | 19 | 98 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 548 | 504 | 472 | 0 | NA |
Retained Earnings | -366 | -231 | -122 | -48 | NA |
Other Equity | -3 | -2 | -2 | -1 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 179 | 271 | 348 | -49 | NA |
Total Liabilities & Shareholder's Equity | 304 | 342 | 366 | 49 | NA |
Total Common Equity | 179 | 271 | 348 | -49 | 0 |
Shares Outstanding | 50.00 | 48.40 | 46.50 | NA | NA |
Book Value Per Share | 3.59 | 5.61 | 7.47 | 0.00 | 0.00 |
Fiscal Year End for Monte Rosa Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 262 | 193 | 232 | 178 | 203 |
Receivables | 10 | 1 | 1 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 6 | 3 | 4 | 4 |
Total Current Assets | 278 | 199 | 236 | 183 | 208 |
Net Property & Equipment | 33 | 34 | 34 | 35 | 35 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 5 | 5 | 5 | 5 |
Total Assets | 344 | 267 | 304 | 252 | 279 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 7 | 11 | 6 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 11 | 15 | 14 | 11 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 20 | 20 | 18 | 0 | 0 |
Total Current Liabilities | 42 | 41 | 47 | 23 | 19 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 36 | 31 | 35 | 1 | 2 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 119 | 114 | 125 | 68 | 65 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 656 | 553 | 548 | 519 | 513 |
Retained Earnings | -428 | -398 | -366 | -333 | -298 |
Other Equity | -3 | -3 | -3 | -1 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 225 | 153 | 179 | 185 | 214 |
Total Liabilities & Shareholder's Equity | 344 | 267 | 304 | 252 | 279 |
Total Common Equity | 225 | 153 | 179 | 185 | 214 |
Shares Outstanding | 50.50 | 50.30 | 50.00 | 49.60 | 49.30 |
Book Value Per Share | 4.45 | 3.03 | 3.59 | 3.72 | 4.33 |